Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10549-015-3345-z | DOI Listing |
Publication Analysis
Top Keywords
erratum platinum-based
4
platinum-based chemotherapy
4
chemotherapy triple-negative
4
triple-negative advanced
4
advanced breast
4
breast cancer
4
erratum
1
chemotherapy
1
triple-negative
1
advanced
1
Similar Publications
Corrigendum to 'A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody': [ESMO Open volume 9 issue 6 (2024) 103476].
ESMO Open
August 2024
Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe; Cancer Center, Kobe University Hospital, Kobe.
Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50].
Lung Cancer
July 2024
Department of Medical Oncology, Kindai University, Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan.
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Cancer Immunol Immunother
June 2023
Department of Medical Oncology, Hospital Foch, Suresnes, France.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!